1. Home
  2. LMT vs VRTX Comparison

LMT vs VRTX Comparison

Compare LMT & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lockheed Martin Corporation

LMT

Lockheed Martin Corporation

N/A

Current Price

$595.43

Market Cap

127.4B

Sector

Industrials

ML Signal

N/A

Logo Vertex Pharmaceuticals Incorporated

VRTX

Vertex Pharmaceuticals Incorporated

N/A

Current Price

$539.20

Market Cap

135.6B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
LMT
VRTX
Founded
1912
1989
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
EDP Services
Sector
Industrials
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
127.4B
135.6B
IPO Year
1995
2006

Fundamental Metrics

Financial Performance
Metric
LMT
VRTX
Price
$595.43
$539.20
Analyst Decision
Buy
Buy
Analyst Count
24
32
Target Price
★ $660.86
$595.36
AVG Volume (30 Days)
★ 1.6M
1.5M
Earning Date
10-22-2026
11-02-2026
Dividend Yield
★ 2.38%
N/A
EPS Growth
N/A
★ 836.54
EPS
★ 22.36
10.90
Revenue
★ $75,048,000,000.00
$2,488,652,000.00
Revenue This Year
$8.48
$10.46
Revenue Next Year
$7.03
$10.53
P/E Ratio
★ $27.07
$50.09
Revenue Growth
5.64
★ 46.20
52 Week Low
$437.25
$412.27
52 Week High
$692.00
$568.67

Technical Indicators

Market Signals
Indicator
LMT
VRTX
Relative Strength Index (RSI) 52.93 53.31
Support Level $593.88 $493.75
Resistance Level $603.26 $561.54
Average True Range (ATR) 17.85 16.77
MACD -3.96 0.07
Stochastic Oscillator 34.07 51.53

Price Performance

Historical Comparison
LMT
VRTX

About LMT Lockheed Martin Corporation

Lockheed Martin is the world's largest defense contractor and has dominated the Western market for high-end fighter aircraft since it won the F-35 Joint Strike Fighter program in 2001. Aeronautics is Lockheed's largest segment, which derives upward of two-thirds of its revenue from the F-35. Lockheed's remaining segments are rotary and mission systems, encompassing the Sikorsky helicopter business; missiles and fire control, which creates missiles and missile defense systems; and space systems, which produces satellites and receives equity income from the United Launch Alliance joint venture.

About VRTX Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is focused on diversifying its portfolio through Casgevy (gene-editing therapy for beta thalassemia and sickle-cell disease), Journavx (non-opioid pain drug for moderate-to-severe acute pain), and Palsonify (for acromegaly). Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases, cell therapies to deliver a functional cure for type 1 diabetes, povetacicept (for IgA nephropathy).

Share on Social Networks: